Cost-effectiveness analysis of a rotavirus immunization program for the United States

JAMA

Volumn 279, Issue 17, 1998, Pages 1371-1736

  Tucker, Andrew W ^a   Haddix, Anne C ^b   Bresee, Joseph S ^a   Holman, Robert C ^d   Parashar, Umesh D ^c   Glass, Roger I ^a,c  

^a Resp and Enteric Viruses Branch   (United States)

^b Epidemiology and Analysis Program Office   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; EMERGENCY WARD; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ROTAVIRUS; UNITED STATES;

EID: 0032490140     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.17.1371     Document Type: Article

References (37)

1. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis. 1996;174(suppl 1):S5-S11.
2. Kapikian AZ. Viral gastroenteritis. JAMA. 1993; 269:627-630.
3. Gurwith M, Wenman W, Hinde D, et al. A prospective study of rotavirus infection in infants and young children. J Infect Dis. 1981;144:218-224.
4. Rodriguez WJ, Kim HW, Brandt CD, et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis. 1987;6:170-176.
5. Parashar UD, Holman RC, Clarke MJ, et al. Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus-specific diagnostic code. J Infect Dis. 1997;177:13-17.
6. Kilgore PE, Holman RC, Clarke MJ, et al. Trends of diarrheal disease-associated mortality in US children, 1968 through 1991. JAMA 1995;274:1143-1148.
7. Jin S, Kilgore PK, Holman RC, et al. Trends in hospitalizations for diarrhea in United States children from 1979-1992: estimates of the morbidity associated with rotavirus. Pediatr Infect Dis J. 1996; 15:397-404.
8. Smith J, Haddix A, Teutsch S, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics. 1995;96:609-615.
9. Bernstein DI, Glass RI, Rodgers G, et al. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA. 1995;273:1191-1196.
10. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics. 1996;97:7-13.
11. Joensuu J, Koskenniemi E, Pang X-L, et al. A randomised, double-blind, placebo controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 1997;350:1205-1209.
12. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med. 1997;337:1181-1209.
13. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr. 1997;131:632-638.
14. Clark HF, Offit PA, Ellis RW, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis. 1996;174(suppl 1):S73-S80.
15. Rodriguez WJ, Kim HW, Brandt CD, et al. Rotavirus gastroenteritis in the Washington, DC area. AJDC. 1980;134:777-779.
16. Matson DO, Estes MK. Impact of rotavirus infection at a large pediatric hospital. J Infect Dis. 1990;162:598-604.
17. Bureau of the Census, US Department of Commerce Economics and Statistics Administration. Current Population Reports: Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050. Washington, DC: US Government Printing Office; 1996.
18. Clemens JD, van Loon FFPL, Rao M, et al. Non-participation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. Am J Epidemiol. 1992;135:865-874.
19. Chalmers TC. A potpourri of RCT topics. Control Clin Trials. 1982;3:285-298.
20. Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials. 1984;5: 115-128.
21. Koopman JS, Turkish VJ, Monto AS, et al. Patterns and etiology of diarrhea in three clinical settings. Am J Epidemiol. 1984;119:114-123.
22. Kotloff KL, Wasserman SS, Steciak JY, et al. Acute diarrhea in Baltimore children attending an outpatient clinic. Pediatr Infect Dis J. 1988;7:753-759.
23. National Center for Health Statistics, Vital and Health Statistics: National Ambulatory Medical Care Survey. US Department of Health and Human Services, National Ambulatory Medical Care Survey: Public Use Data Tape Documentation 1993. Hyattsville, Md: Centers for Disease Control and Prevention, National Center for Health Statistics; 1996.
24. National Center for Health Statistics: National Hospital Ambulatory Medical Care Survey. US Department of Health and Human Services. National Hospital Ambulatory Medical Care Survey, Public Use Data Tape Documentation 1994. Hyattsville, Md: Centers for Disease Control and Prevention, National Center for Health Statistics; 1996.
25. Gurwith M, Wenman W, Gurwith D, et al. Diarrhea among infants and young children in Canada: a longitudinal study in three northern communities. J Infect Dis. 1983;147:685-692.
26. Advisory Committee on Immunization Practices. Rotavirus Vaccines for the Prevention of Rotavirus Diarrhea in Children (Draft Recommendations). Atlanta, Ga: Centers for Disease Control and Prevention; October 1997:1-17.
27. Centers for Disease Control and Prevention: Reported Vaccine-Preventable Disease - United States, 1993, and the Childhood Immunization Initiative. MMWR Morb Mortal Wkly Rep. 1994;43: 57-60.
28. Chung MA. Diarrheal Hospitalization Trends in Children in Connecticut From 1985 to 1996: A Comparison of Estimate and Crude Rotavirus Disease Burden [thesis]. New Haven, Conn: Yale University School of Medicine, Dept of Epidemiology and Public Health; 1997.
29. Avendano P, Matson DO, Long J, et al. Costs associated with office visits for diarrhea in infants and toddlers. Pediatr Infect Dis J. 1993;12:897-902.
30. Gonzalez ML. Socioeconomic Characteristics of Medical Practice. Chicago, Ill: American Medical Association; 1996:77-79.
31. HealthCare Consultants of America. I, 1996 Physician Fee and Coding Guide: A Comprehensive Fee and Coding Reference. Augusta, Ga: Health Care Consultants; January 1996:42.
32. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271:375-381.
33. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. JAMA. 1995;274:1201-1208.
34. Haddix A, Teutsch S, Shaffer P, et al, eds. A Practical Guide to Prevention Effectiveness: Decision and Economic Analyses. Atlanta, Ga: Centers for Disease Control and Prevention; 1994.
35. Glass RI, Ho MS, Lew JF, et al. SAREC Conference Report: Cost-benefit studies of rotavirus vaccines in the United States. In: Sack DA, Freij L, eds. Prospects for Public Health Benefits in Developing Countries From New Vaccines Against Enteric Infections. Stockholm, Sweden: Gotab; 1990: 102-107.
36. Griffiths RI, Anderson GF, Powe NR, et al. Economic impact of immunization against rotavirus gastroenteritis. Arch Pediatr Adolesc Med. 1995;149: 407-414.
37. Ho M-S, Glass RI, Pinsky PF, et al. Rotavirus as a cause of diarrheal morbidity and mortality in the United States. J Infect Dis. 1988;158:1112-1116.